The ROMA® (Risk of Ovarian Malignancy Algorithm) calculation combines the results of the Roche Elecsys HE4 assay, Elecsys CA 125 II assay and menopausal status into a numerical score (Roche). The ROMA value is intended to aid in assessing whether a premenopausal or postmenopausal woman who presents with an ovarian adnexal mass is at high or low likelihood of finding malignancy on surgery. ROMA Calculation is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned and not yet referred to an oncologist. ROMA values must be interpreted in conjunction with an independent clinical and radiological assessment. The test is not intended as a screening or stand-alone diagnostic assay.
This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of Biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R).
It is recommended to ask all patients who may be indicated for this test about Biotin supplementation. Patients should be cautioned to stop Biotin consumption at least 72 hours prior to the collection of a sample.
Gold serum separator (SST) tube
Spin and separate
Refrigerated (preferred) - 14 days
Ambient - 14 days
Electrochemiluminescence Immunoassay (ECLIA)
An interpretive report will be provided